GlassScriptPhysician profile
Mark James Flood
NPI 1376729046
$9,391.48
in general payments reported to CMS, 2019-2025
28 companies · $976 in 2025
The $976 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $976 · 2021: $1,708 · 2022: $1,981 · 2023: $1,810 · 2024: $1,274 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,060.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,243.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,046.00 | 2021-2025 | Vraylar |
| Bausch Health US, LLC | $796.18 | 2019-2024 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $698.08 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $666.20 | 2019-2024 | Rexulti, Abilify Mycite |
| Neurocrine Biosciences, INC. | $656.28 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $612.11 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $543.40 | 2019-2022 | |
| Alkermes, INC. | $529.19 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $405.55 | 2020-2025 | Caplyta |
| Almatica Pharma LLC | $376.75 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $314.81 | 2022-2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $291.35 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $145.19 | 2019-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $140.26 | 2022-2024 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $138.19 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Axsome Therapeutics, INC. | $131.20 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $128.83 | 2019-2023 | Spravato, Invega, Invega Sustenna |
| Corium, LLC | $124.00 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $100.89 | 2019-2024 | |
| Noven Therapeutics, LLC | $87.39 | 2020-2024 | Xelstrym |
| Allergan, INC. | $78.86 | 2019-2020 | |
| Adlon Therapeutics L.P. | $29.68 | 2019-2020 | |
| Eisai INC. | $27.87 | 2020 | |
| Avanir Pharmaceuticals, INC. | $26.07 | 2020 | |
| Vertical Pharmaceuticals, LLC | $23.11 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.